Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Circulating 1,25-dihydroxyvitamin D was not independently associated with iPTH response.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Secondary analysis.

Secondary analysis

Analyses existing study data; this paper is not automatically another independent trial.

Meta-analysis unclear · Double-blind reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This post-hoc analysis used pooled data from two identical randomized, double-blind, placebo-controlled clinical trials (NCT1651000, ) evaluating 26 weeks of daily oral ERC treatment in participants with SHPT, CKD stage 3 or 4, and VDI, operationally defined as serum total 25D < 30 ng/ml.

Source: Methods.

This post-hoc analysis used pooled data from two identical randomized, double-blind, placebo-controlled clinical trials (NCT1651000, ) evaluating 26 weeks of daily oral ERC treatment in participants with SHPT, CKD stage 3 or 4, and VDI, operationally defined as serum total 25D < 30 ng/ml.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Extended-release calcifediol identifies a therapeutic vitamin D range in chronic kidney disease stages 3 and 4

Secondary analysis · Clinical Kidney Journal · 2026

Original publication title

Extended-release calcifediol identifies a therapeutic vitamin D range in chronic kidney disease stages 3 and 4

John Choe; Akhtar Ashfaq; Charles W Bishop

© The Author(s) 2026. Published by Oxford University Press on behalf of the ERA.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Elevation of 25D to 84 ng/ml (range: 66.9 to 102.6 ng/ml) during ERC treatment was associated with a 30% iPTH reduction in participants with SHPT, CKD stage 3 to 4, and VDI. This range was unassociated with adverse changes in mineral metabolism.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD) driven by dysregulated vitamin D metabolism. The serum 25-hydroxyvitamin D (25D) levels required for targeted intact parathyroid hormone (iPTH) reductions are poorly defined, and conventional sufficiency thresholds of 20 or 30 ng/ml are inadequate. Exposure: response (E: R) modeling was used to define a 25D range associated with a 30% iPTH reduction during treatment with extended-release calcifediol (ERC).

Source: Background

Abstract: What methods does the paper describe?

E: R relationships between 25D and iPTH were evaluated using pooled data from randomized clinical trials of ERC in participants with SHPT, CKD stage 3 to 4, and vitamin D insufficiency (VDI). Mixed-effects models characterized percent change in iPTH as a function of concurrent 25D. Mechanistic analyses evaluated associations between 25D, its key metabolites, and iPTH. Associations between achieved 25D and markers of mineral metabolism were assessed.

Source: Methods

Abstract: Results

E: R modeling demonstrated a nonlinear relationship between 25D and iPTH reduction with a population-average of 84 ng/ml associated with 30% iPTH reduction (ER30), ranging from 67 to 103 ng/ml across the range of kidney function. Baseline body weight and sex significantly influenced achieved 25D concentrations. Higher achieved 25D was not associated with adverse changes in calcium, phosphorus, or fibroblast growth factor 23. Circulating 1,25-dihydroxyvitamin D was not independently associated with iPTH response.

Source: Results

Abstract: Conclusions

Elevation of 25D to 84 ng/ml (range: 66.9 to 102.6 ng/ml) during ERC treatment was associated with a 30% iPTH reduction in participants with SHPT, CKD stage 3 to 4, and VDI. This range was unassociated with adverse changes in mineral metabolism.

Source: Conclusions
Authors’ abstract

ABSTRACT

Background

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD) driven by dysregulated vitamin D metabolism. The serum 25-hydroxyvitamin D (25D) levels required for targeted intact parathyroid hormone (iPTH) reductions are poorly defined, and conventional sufficiency thresholds of 20 or 30 ng/ml are inadequate. Exposure: response (E: R) modeling was used to define a 25D range associated with a 30% iPTH reduction during treatment with extended-release calcifediol (ERC).

Methods

E: R relationships between 25D and iPTH were evaluated using pooled data from randomized clinical trials of ERC in participants with SHPT, CKD stage 3 to 4, and vitamin D insufficiency (VDI). Mixed-effects models characterized percent change in iPTH as a function of concurrent 25D. Mechanistic analyses evaluated associations between 25D, its key metabolites, and iPTH. Associations between achieved 25D and markers of mineral metabolism were assessed.

Results

E: R modeling demonstrated a nonlinear relationship between 25D and iPTH reduction with a population-average of 84 ng/ml associated with 30% iPTH reduction (ER30), ranging from 67 to 103 ng/ml across the range of kidney function. Baseline body weight and sex significantly influenced achieved 25D concentrations. Higher achieved 25D was not associated with adverse changes in calcium, phosphorus, or fibroblast growth factor 23. Circulating 1,25-dihydroxyvitamin D was not independently associated with iPTH response.

Conclusions

Elevation of 25D to 84 ng/ml (range: 66.9 to 102.6 ng/ml) during ERC treatment was associated with a 30% iPTH reduction in participants with SHPT, CKD stage 3 to 4, and VDI. This range was unassociated with adverse changes in mineral metabolism.

Publication and source details

Original title: Extended-release calcifediol identifies a therapeutic vitamin D range in chronic kidney disease stages 3 and 4

John Choe; Akhtar Ashfaq; Charles W Bishop

Clinical Kidney Journal · 2026

Correspondence to: John Choe; E-mail: jchoe@opko.com© The Author(s) 2026. Published by Oxford University Press on behalf of the ERA.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. OPKO Health, Inc.10.13039/100015851

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-09T20:28:13.986127+00:00

DOI: 10.1093/ckj/sfag194 · PMC13370826